Information:
Fel:
ID
42742
Beskrivning
Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01536028
Länk
https://clinicaltrials.gov/show/NCT01536028
Nyckelord
Versioner (2)
- 2017-03-16 2017-03-16 -
- 2021-09-17 2021-09-17 -
Uppladdad den
17 september 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Diabetes NCT01536028
Eligibility Diabetes NCT01536028
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT01536028
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Insulin-Dependent Diabetes Mellitus disease length
Item
type 1 diabetes for at least 12 months
boolean
C0011854 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0872146 (UMLS CUI [1,2])
C-peptide Maximum
Item
serum c-peptide maximum 0.4 ng/ml
boolean
C0006558 (UMLS CUI [1,1])
C0806909 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,2])
Therapeutic procedure Bolus Basis | Insulin soluble human | Insulin Lispro | Insulin, Glulisine | insulin, isophane | insulin detemir | Insulin Glargine
Item
current basal bolus treatment with soluble human insulin, insulin lispro, insulin glulisine, nph insulin, insulin detemir or insulin glargine
boolean
C0087111 (UMLS CUI [1,1])
C1705509 (UMLS CUI [1,2])
C1527178 (UMLS CUI [1,3])
C0795635 (UMLS CUI [2])
C0293359 (UMLS CUI [3])
C1313386 (UMLS CUI [4])
C0021658 (UMLS CUI [5])
C0537270 (UMLS CUI [6])
C0907402 (UMLS CUI [7])
C1705509 (UMLS CUI [1,2])
C1527178 (UMLS CUI [1,3])
C0795635 (UMLS CUI [2])
C0293359 (UMLS CUI [3])
C1313386 (UMLS CUI [4])
C0021658 (UMLS CUI [5])
C0537270 (UMLS CUI [6])
C0907402 (UMLS CUI [7])
Body mass index
Item
bmi (body mass index) maximum 32 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Glycosylated hemoglobin A Percentage Maximum
Item
hba1c (glycosylated haemoglobin) maximum 9% based on analysis from central laboratory
boolean
C0019018 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
C0439165 (UMLS CUI [1,2])
C0806909 (UMLS CUI [1,3])
Non-smoker
Item
non-smoker
boolean
C0337672 (UMLS CUI [1])
Investigational New Drugs
Item
the receipt of any investigational drug within the last 30 days prior to this trial
boolean
C0013230 (UMLS CUI [1])
Insulin Cumulative Dose U/day
Item
total daily insulin dose at least 1.8 u/kg/day
boolean
C0021641 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
C2986497 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
Insulin Aspart
Item
current treatment with iasp (insulin aspart) products
boolean
C1708521 (UMLS CUI [1])
Substance Use Disorders
Item
a history of drug or alcohol abuse within the last 5 years
boolean
C0038586 (UMLS CUI [1])
Liver Dysfunction
Item
impaired hepatic function
boolean
C0086565 (UMLS CUI [1])
Renal Insufficiency
Item
impaired renal function
boolean
C1565489 (UMLS CUI [1])
cardiac problem
Item
cardiac problems
boolean
C0262402 (UMLS CUI [1])
Uncontrolled hypertension Severe
Item
severe, uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0205082 (UMLS CUI [1,2])